Peter Sazani

Pete brings more than 16 years of executive leadership experience in preclinical drug development in small and medium biotech with expertise spanning multiple disease areas including oncology, neuromuscular and infectious diseases. Prior to joining Morphiex, Pete was the Head of Medical Affairs and Patient Advocacy at Marathon Pharmaceuticals, leading medical and patient outreach to accelerate FDA approval of Emflaza, a treatment for Duchenne Muscular Dystrophy (DMD). Pete was also the Executive Director of Preclinical Development and Medical Affairs at Sarepta Therapeutics where he led multiple IND applications including the recently approved Exondys51 for DMD. Prior to that, Pete was co-founder of Ercole Biotech, a startup company devoted to the developing oligonucleotides that control pre-mRNA splicing as therapeutics which ultimately led to the development of Exondys51. Pete obtained his PhD from The University of North Carolina at Chapel Hill in Pharmacology and his Bachelor’s in Biochemistry from Binghamton University.